Download PDF
Hamostaseologie 2002; 22(01): 45-48
DOI: 10.1055/s-0037-1622008
Original Article
Schattauer GmbH

Faktor XIII und Wundheilung

Factor XIII and wound healing
G. Wozniak
1   Klinik für Gefäßchirurgie, Knappschaftskrankenhaus Bottrop (Leiter: Priv.-Doz. Dr. med. G. Wozniak)
,
Th. Noll
2   Physiologisches Institut, Justus-Liebig-Universität Gießen (Leiter: Prof. Dr. Dr. H. M. Piper)
› Author Affiliations
Further Information

Publication History

Publication Date:
29 December 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Neben den Wunden, bei denen sich im Rahmen der gestörten Heilung eine zunehmende Fragilität der Kapillarstrombahn bildet, sind es vor allem die chronischen Wunden im Zusammenhang mit einem langjährigen Diabetes mellitus oder einer chronischvenösen Insuffizienz, oft infolge eines postthrombotischen Syndroms, bei denen die Permeabilitätsstörung im Sinne einer gesteigerten vaskulären Durchlässigkeit eine eigenständige Problematik darstellt, deren Beherrschung von großem therapeutischen Interesse ist. In der jüngsten Vergangenheit hat sich sowohl in klinischen als auch in experimentellen Untersuchungen gezeigt, dass die Plasmatransglutaminase (Faktor XIIIa) hier einen neuen Ansatz bieten könnte.

Summary

In addition to those wounds with increasing fragility of capillaries during impaired healing, there are especially long lasting diabetic wounds or calf ulcerations due to chronic venous insufficiency or postthrombotic syndrome that show a failure of endothelial barrier function with an increased permeability as an important part of its pathophysiological situation. The possibility of controlling this increased permeability is of great therapeutical interest and may give distinct benefit for wound healing. In the close past, clinical as well as experimental studies revealed the plasma transglutaminase (factor XIIIa) as potential new strategy in treatment of increased vascular permeability.

Schlüsselwörter

Chronische Wunde - Geweberegeneration - Schrankenfunktionsstörung

Keywords

Chronic wound - tissue regeneration - barrier failure
 

  • Literatur

  • 1 Ádány R, Bárdos H, Muszbek L. Factor XIII in tumor matrix formation and remodelling. Blood Coagul Fibrinolysis 1995; 6: 338.
    PubMedGoogle Scholar
  • 2 Ádány R, Kiss A, Muszbek L. Factor XIII: a marker of mono- and megakaryocytopoiesis. Br J Haematol 1987; 67: 167-72.
    CrossrefPubMedGoogle Scholar
  • 3 Altmeyer P. Der Wundheilungsprozess aus heutiger Sicht. Sedlarik KM, Lippert H. (Hrsg) Wundheilung und Wundauflagen. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH. 1996: 32-5.
    Google Scholar
  • 4 Benfer J, Struck H. Factor XIII and fracture healing. Europ Surg Res 1977; 9: 217-23.
    CrossrefPubMedGoogle Scholar
  • 5 Bollinger A, Herrig I, Fischer M, Hoffmann U, Franzeck UK. Intravital capillaroscopy in patients with chronic venous insufficiency and lymphoedema: relevance to Daflon 500 mg. Int J Microcirc Clin Exp 1995; 15 (Suppl 1) 41-4.
    CrossrefPubMedGoogle Scholar
  • 6 Bruhn HD, Cristhophers E, Pohl J. Einflüsse des Gerinnungs- und Fibrinolysesystems auf den Wundheilungsprozess und die Thrombusorganisation. Verh Dtsch Ges Inn Med 1987; 84: 1345-8.
    PubMedGoogle Scholar
  • 7 Bruhn HD, Zurborn KH. Influences of clotting factors (thrombin, factor XIII) and of fibronectin on the growth of tumor cells and leukemic cells in vitro. Blut 1983; 46: 85-8.
    CrossrefPubMedGoogle Scholar
  • 8 Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432-8.
    CrossrefPubMedGoogle Scholar
  • 9 Ciano PS, Colvin RB, Dvorak AM, McDonagh J, Dvorak HF. Macrophage migration in fibrin gel matrices. Lab Invest 1986; 54: 62-70.
    PubMedGoogle Scholar
  • 10 Cohen I, Blankenberg TA, Borden D, Kahn DR, Veis A. Factor XIIIa-catalyzed crosslinking of platelet and muscle actin. Regulation by nucleotides. Biochim Biophys Acta 1980; 628: 365-75.
    CrossrefPubMedGoogle Scholar
  • 11 Constantini V, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM. Fibrinogen deposition without thrombin generation in primary human breast cancer tissue. Cancer Res 1991; 51: 349-53.
    PubMedGoogle Scholar
  • 12 Curtis CG, Brown KL, Credo RB, Domanik RA, Gray A, Stenberg P, Lorand L. Calciumdependent unmasking of active-center cysteine during activation of fibrin stabilizing factor. Biochemistry 1974; 13: 3774-80.
    CrossrefPubMedGoogle Scholar
  • 13 Dormandy JA. Microcirculation in venous disorders: The role of white blood cells. Int J Microcirc 1995; 15 Suppl 1 3-8.
    CrossrefPubMedGoogle Scholar
  • 14 Folk JE. Mechanism and basis for specificity of transglutaminase-catalyzed epsilon-(gamma- glutamyl) lysine bond formation. Adv Enzymol 1983; 54: 1-56.
    PubMedGoogle Scholar
  • 15 Grivaux M, Pieron R. Carcinome bronchioloalvéolaire compliquant une sclérodermie généralisée traitée au long cours par le facteur XIII. Rev Pneumol Clin 1987; 43: 102-3.
    PubMedGoogle Scholar
  • 16 Hornyak TJ, Shafer JA. Interactions of factor XIII with fibrin as substrate and cofactor. Biochemistry 1992; 31: 423-9.
    CrossrefPubMedGoogle Scholar
  • 17 Ichinose A, Davie EW. Primary structure of human coagulation factor XIII. Adv Exp Med Biol 1988; 231: 15-27.
    PubMedGoogle Scholar
  • 18 Janzen RWC, Bauer W, Tilsner V. The spontaneous course of factor XIII following intracranial hemorrhage: relevant for re-bleeding?. J Neurosurg Sci 1982; 26: 135-6.
    PubMedGoogle Scholar
  • 19 Kaczmarek E, Liu Y, Berse B, Chen CS, McDonagh J. Biosynthesis of plasma factor XIII: evidence for transcription and translation in hepatoma cells. Biochim Biophys Acta 1995; 1247: 127-34.
    CrossrefPubMedGoogle Scholar
  • 20 Kloczko J, Wojtukiewicz M, Bielawiec M, Zarzycka B, Kinalska I. Plasma factor XIII and some other haemostasis parameters in patients with diabetic angiopathy. Acta Haematol 1986; 76: 81-5.
    CrossrefPubMedGoogle Scholar
  • 21 Kloczko J, Wojtukiewicz M, Bielawiec M, Zuch A. Alterations of haemostasis parameters with special reference to fibrin stabilization, factor XIII and fibronectin in patients with obliterative atherosclerosis. Thromb Res 1988; 51: 575-81.
    CrossrefPubMedGoogle Scholar
  • 22 Korsgren C, Cohen CM. Organization of the gene for human erythrocyte membrane protein 4.2: structural similarities with the gene for the a subunit of factor XIII. Proc Natl Acad Sci USA 1991; 88: 4840-4.
    CrossrefPubMedGoogle Scholar
  • 23 Kradin RL, Lynch GW, Kurnick JT, Erikson M, Colvin RB, McDonagh J. Factor XIIIa is synthesized and expressed on the surface of U-937 cells and alveolar macrophages. Blood 1987; 69: 778-85.
    PubMedGoogle Scholar
  • 24 Leu AJ, Yanar A, Pfister G, Geiger M, Franzeck UK, Bollinger A. Microangiopathy in chronic venous insufficiency. Dtsch Med Wochenschr 1991; 116: 447-53.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 McDonagh J. Biochemistry of fibrin-stabilizing factor (XIII). In: McDonagh J, Seitz R, Egbring R. (eds) Factor XIII. Stuttgart: Schattauer Verlag; 1993: 2-8.
    Google Scholar
  • 26 McDonagh J. Biochemistry of factor XIII and fibrin stabilization. Blood Coagul Fibrinolysis 1995; 6: 334.
    PubMedGoogle Scholar
  • 27 Nagy JA, Henriksson P, McDonagh J. Biosynthesis of factor XIII B subunit by human hepatoma cell lines. Blood 1986; 68: 1272-9.
    PubMedGoogle Scholar
  • 28 Nagy JA, Kradin RL, McDonagh J. Biosynthesis of factor XIII A and B subunits. In: Zappia V, Galletti P, Porta R, Wold F. (Hrsg). Post-Translational modification of proteins. New York: Plenum Press; 1988: 29-49.
    Google Scholar
  • 29 Nawroth PP, Lu J, Abel M, Zhang Y, Riedesel FZE, Bierhaus A, Liliensiek B, Vettermann Th, Lin J, Kasperk C, Ziegler R. Endothelzellstimulation durch AGE - Ein In-vitro-Modell diabetischer Spätschäden. In: Hasslacher C, Spanuth E. (Hrsg) Diabetes und Angiopathie. Berlin: Springer-Verlag; 1993: 33-7.
    CrossrefGoogle Scholar
  • 30 Nemes Z, Thomazy V. Factor XIIIa and the classic histiocytic markers in malignant fibrous histiocytoma: a comparative immunohistochemical study. Hum Pathol 1988; 19: 822-9.
    CrossrefPubMedGoogle Scholar
  • 31 Noll T, Wozniak G, McCarson K, Hajimohammad A, Metzner HJ, Inserte J, Kummer W, Hehrlein FW, Piper HM. Effects of factor XIII on endothelial barrier function. J Exp Med 1999; 189: 1373-82.
    CrossrefPubMedGoogle Scholar
  • 32 Payé M, Lapière CHM. Wundheilung: Der Beitrag des Gerinnungsfaktors XIII. Die gelben Hefte 1986; 26: 128-35.
    PubMedGoogle Scholar
  • 33 Payé M, Lapière CHM. The lack of attachment of transformed embryonic lung epithelial cells to collagen I is corrected by fibronectin and factor XIII. J Cell Sci 1986; 86: 95-107.
    PubMedGoogle Scholar
  • 34 Poon MC, Russell JA, Low S, Sinclair GD, Jones AR, Blashey W, Ruether BA, Hoar DI. Hemopoietic origin of factor XIII A subunits in platelets, monocytes, and plasma. Evidence from bone marrow transplantation studies. J Clin Invest 1989; 84: 787-92.
    CrossrefPubMedGoogle Scholar
  • 35 Reitz M, Witzke G, Egbring R, Gutjahr P. Coagulation factors and proteinase inhibitors in the plasma of children with acute lymphoblastic leukoses. Klin Wochenschr 1984; 62: 1165-9.
    CrossrefPubMedGoogle Scholar
  • 36 Sakata Y, Aoki M. Crosslinking of alpha2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65: 290-7.
    CrossrefPubMedGoogle Scholar
  • 37 Shainoff JR, Valenzuela R, Urbanic DA, DiBello PM, Lucas FV, Graor R. Fibrinogen A alpha and gamma-chain dimers as potential differential indicators of atherosclerotic and thrombotic vascular disease. Blood Coagul Fibrinolysis 1990; 1: 499-503.
    CrossrefPubMedGoogle Scholar
  • 38 Toida M, Okumura Y, Swe-Win KK, Oka N, Takami T, Adany R. Characterization of cells containing factor XIII subunit a in benign and malignant buccal lesions. Histochem J 1995; 27: 449-56.
    PubMedGoogle Scholar
  • 39 Turnock K, Bulmer JN, Gray C. Phenotypic characterization of macrophage subpopulations and localization of factor XIII in stromal cells of carcinomas. Histochem J 1990; 22: 661-6.
    CrossrefPubMedGoogle Scholar
  • 40 Wozniak G, Dapper F, Alemany J. Factor XIII in ulcerative leg disease: background and preliminary clinical results. Semin Thromb Hemost 1996; 22: 445-50.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Wozniak G, Harbarth P, Segelken K, Alemany J. Der Einfluss des aktuellen Gerinnungsstatus auf das Ergebnis der semilokalen rt-PA-Lyse bei der distalen Zwei-Etagen-Venenthrombose. Hämostaseologie 1995; 15: 225-31.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Wozniak G, Lutz H, Noll T, Alemany J. Behandlung stark sekretierender, chronischer Wunden mit Faktor XIII: III – Klinische Modalitäten und Ergebnisse. ZfW 2001; 20: 10-3.
    PubMedGoogle Scholar
  • 43 Wozniak G, Montag H, Alemany J. Lokalapplikation von Faktor XIII zur Therapie cruraler Ulcerationen bei Patienten mit postthrombotischer Anamnese: klinische Bewertung einer Pilotuntersuchung. Vasomed 1993; 5: 644-51.
    PubMedGoogle Scholar
  • 44 Wozniak G, Noll T, Bott U, Hehrlein FW. Faktor XIII: experimentelle und klinische Ergebnisse beim diabetischen Malum perforans. Zentralbl Chir 1999; 124 (Suppl 1): 73-7.
    PubMedGoogle Scholar
  • 45 Wozniak G, Noll T, Brunner U, Hehrlein FW. Topical treatment of venous ulcer with fibrin stabilizing factor: experimental investigation of effects on vascular permeability. VASA 1999; 28: 160-3.
    CrossrefPubMedGoogle Scholar
  • 46 Wozniak G, Noll T, Dapper F, Piper HM, Hehrlein FW. The fibrin-stabilizing factor as a topical means for leg ulcer healing: biochemical and experimental properties and clinical results. Int J Angiol 1998; 7: 109-14.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Wozniak G, Noll T, Hehrlein FW. Einfluss von Faktor XIII auf die endotheliale Barriere – Klinik und Experiment. In: Egbring R, Seitz R, Wozniak G. (Hrsg). Klinische Aspekte des Faktor-XIII-Mangels Basel: Karger; 1999: 16-25.
    Google Scholar